跳至主要内容
临床试验/NCT03878433
NCT03878433已完成不适用

Oral Superoxide Dismutase (GLISODin) to Decrease Melasma Severity. A Prospective Randomized Placebo-controlled Study

Centre Hospitalier Universitaire de Nice1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2019年4月1日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
状态
已完成
入组人数
40
试验地点
1
主要终点
Severity of melasma

研究概览

简要总结

Oxidative stress has been reported to play a role in melasma pathophysiology. The objective of the study is to compare oral superoxide dismutase (GLISODin) to placebo, in combination to sunscreen to decrease melasma severity.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Clinically diagnosed melasma in adult patient
  • signed inform consent

排除标准

  • Pregnant women
  • Other pigmentary disorder of the afce
  • Use of depigmentant agent in the month before the inclusion
  • Use of topical steroid, tretinoin, hydroquinone in the month before the inclusion
  • Coeliac disease or allergy to gluten

研究组 & 干预措施

Drug

Active Comparator

Glisodin : 2 capsules of GliSODin, 500mg of GliSODIn per day. Preferably to take in the morning during breakfast

干预措施: Glisodin (Drug)

No Drug

Placebo Comparator

2 capsules of PLacebo, 500mg of Placebo per day. Preferably to take in the morning during breakfastbo

干预措施: placebo (Other)

结局指标

主要结局

Severity of melasma

时间窗: At baseline and at 12 weeks

Change from Baseline of the Modified Melasma Area and Severity Index (mMASI) total score at 12 months. The MASI is 0 à 24 : Front 0.3(D)(A)+ right malar 0.30(D)(A)+ left malar 0.30(D)(A)+ chin 0.1(D)(A)

次要结局

  • Satisfaction of the patients: VAS (Visual Analog Scale)(At baseline and at 12 weeks)
  • Quality of life of patient: VAS (Visual Analog Scale)(At baseline and at 12 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验